PancreaCell Unveils Total Pancreas Regeneration Device Ahead of ADA

Diabetes is one of the diseases associate with the greatest cost in terms of patient suffering, morbidity and mortality, as well as cost to the health care system, costing an average of $250 billion per year. There are now over 30 million people with diabetes, but this total is expected to grow to over 50 million by 2030, influenced in part by both the obesity epidemic. These statistics are a mandate to find new therapies that can not only halt progression of this disease, but seek cures.  To date, the treatment of diabetes has been primarily focused on various new forms of insulin and drugs to reduce blood glucose, and insulin pumps. Other more aggressive treatment approaches have included transplantation of either partial or whole pancreas, which require multiple immunosuppressive drugs and have not had much success to date. Until now, no treatment hasbeen developed that is designed to actually regenerate the native pancreas and insulin producing cells with a goal of curing the disease. Leonhardt Ventures has developed a new cutting edge approach to hopefully cure Diabetes called Pancreacell.  This very innovative program combines bioelectric stimulation of the pancreas that triggers the release of most of the growth factors and trophic proteins that individually have been shown to be very effective in restoring organ function, and collectively also aid recruitment of stem cells to stimulate native repair and regeneration of the pancreas.  The promise of this innovative approach have led Dr. Camillo Ricordi, the Director of the prestigious Diabetes Institute at the University of Miami to become the Scientific Director of Pancreacell. Pre-clinical studies are now under way, and will soon lead to the first in man trials to demonstrate the safety and efficacy of this therapy in patients with both Type I and Type IIdisease. The goal is total elimination of the need for insulin, and a cure for Diabetes.  
 


-Dr. Leslie Miller